touchINFECTIOUS DISEASES spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D.
- What are the unmet needs in diagnosis and treatment of hepatitis? (0:20)
Disclosures: Dr Thomas Berg has received grant/research support from Abbvie, Gilead, and MSD/Merck; and is on the advisory board for Abbvie, Gilead, GSK, Janssen, and MSD/Merck; and is also a speaker’s bureau participant with Abbvie, Gilead, and MSD/Merck.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Hepatitis
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Marina Klein, AIDS2022: Triple elimination of HIV, HCV and HBV
Dr Marina Klein (McGill University Health Centre, Montreal, Canada) joins touchINFECTIOUS DISEASES to discuss triple elimination of three infections (HIV, HBV and HCV) prevalent in low- and middle-income countries. Dr Klein highlights the challenges of transmission of HIV, hepatitis B and hepatitis C. She also looks current therapies for HIV, the elimination of Hepatitis C, […]
Anchalee Avihingsanon, AIDS2022: Bictegravir/FTC/TAF vs dolutegravir in HIV/HBV coinfected adults – ALLIANCE study interim results
The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs dolutegravir plus FTC and TDF. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!